---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-22-013057"
form_type: "8-K"
ticker: "IMRX"
cik: "0001790340"
company_name: "Immuneering Corp"
filed_at: "2022-08-10T23:59:59+00:00"
generated_at: "2026-06-24T01:31:07.227321+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Immuneering Q2 net loss $11.5M; IND for IMM-1-104 on track this quarter

## Summary
- Net loss of $11.5M ($0.44 per share) vs $8.0M ($1.61) in Q2 2021.
- Cash and marketable securities $128.1M as of June 30, 2022, down from $150.2M at Dec 31, 2021.
- Management reiterates FY 2022 GAAP operating expense guidance of $55M-$60M.
- IND filing for IMM-1-104 (pan-KRAS/NRAS) expected this quarter; first patient enrollment expected Q4 2022.
- IND application for IMM-6-415 (MEK-IO program) expected in 2023.

## SEC filing metadata
- accession: 0001558370-22-013057
- form_type: 8-K
- ticker: IMRX
- cik: 0001790340
- company_name: Immuneering Corp
- filed_at: 2022-08-10T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1790340/000155837022013057/0001558370-22-013057-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1790340/000155837022013057/imrx-20220810x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-22-013057
- JSON: https://secwatch.observer/filing/0001558370-22-013057.json
- Plain text: https://secwatch.observer/filing/0001558370-22-013057.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.